Global Antibiotic R&D Partnership Webinar – November 13

CDD Vault Webinar Logo

"Making Safety a Part of Drug Design" with Claire Sadler

Moderated by Ursula Theuretzbacher

November 13, 2018 ・ 8:00AM (PST), 11:00 (EST) and 17:00 (CET)

Don't miss this relevant drug discovery and antimicrobial R&D webinar presented live by CDD Partner, GARDP (the Global Antibiotic Research & Development Partnership)

In this webinar, moderated by Ursula Theuretzbacher from Austria's Center for Anti-Infective Agents, Claire Sadler discusses the toxicological challenges and pitfalls of antibiotic discovery programs.

Potential safety risks are the major reason for terminating a program in the early phases of antibiotic drug development. This webinar will help in identifying the most common toxicology risks associated with antibiotic discovery and discuss potential mitigating strategies.

This presentation was also part of the "Antibiotic Bootcamp for Developers" on Preclinical Toxicology at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, 2018

Register now for this free webinar or learn more about GARDP and the webinar by clicking on the links below:

Featuring these leading scientists...


Clare Sadler

Senior Toxicologist, ApconiX, UK

Clare Sadler is an experienced project toxicologist  with the consultancy ApconiX Ltd in the UK.

Previously Director of UK Discovery Safety at AstraZeneca, Claire designs and implements bespoke safety packages that incorporate in vitro and in vivo experiments.

Addressing safety issues in order to provide a prospective understanding of the major safety risks, her aim is to influence chemical design, creating mitigation strategies and expediting progression through GLP-safety studies and initiation of clinical trials.

Claire has worked primarily in the Oncology and Infection therapeutic areas, with direct involvement in multiple compounds progressing into clinical trials.

Ursula Theuretzbacher, Ph.D.

Ursula Theuretzbacher


A microbiologist focused on antibacterial drug R&D, Ursula Theuretzbacher work aims to improve the use of anti-infectives to increase effectiveness, reduce harm, and combat resistance.

Specialized in antibiotics and antifungals, Dr. Theuretzbacher, has an expertise in international business and government R&D guidance and science communication to clinical, research, and policy bodies.